Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
Precision Drilling
PDS
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 56.04%31.46M | 3,071.94%6.22M | -15.64%6.87M | 983.87%8.4M | -9.73%9.97M | -9.55%20.16M | 115.10%196K | 112.03%8.14M | -91.02%775K | -0.59%11.04M |
Net income from continuing operations | 100.24%13.41M | 639.15%2.91M | -24.27%3.04M | 884.62%3.88M | -3.50%3.59M | 410.96%6.7M | 88.25%-539K | 184.21%4.01M | -155.13%-494K | 2,825.20%3.72M |
Operating gains losses | 44.40%-283K | -450.00%-154K | 88.43%-42K | 128.74%50K | -756.25%-137K | -265.26%-509K | -70.86%44K | -294.12%-363K | -1,187.50%-174K | 65.22%-16K |
Depreciation and amortization | 1.10%21.81M | 4.44%5.6M | -0.82%5.47M | -1.50%5.31M | 2.37%5.44M | -4.43%21.57M | -15.89%5.36M | 2.45%5.51M | 0.24%5.39M | -2.41%5.31M |
Deferred tax | 878.08%714K | -6.23%-870K | 133.70%122K | 77.28%952K | -28.87%510K | -92.51%73K | -100.24%-819K | -172.55%-362K | -7.89%537K | 137.42%717K |
Other non cash items | -304.09%-4.64M | -1,278.39%-3.22M | 179.16%1.09M | -55.71%-1.01M | -348.52%-1.51M | 32.17%-1.15M | -91.10%273K | 23.98%-1.38M | 74.72%-648K | 260.00%608K |
Change In working capital | 88.72%-1.42M | 127.20%2.44M | -1,139.62%-3.29M | 61.69%-1.6M | 21.03%1.03M | -1,328.13%-12.58M | -11.01%-8.98M | 74.62%-265K | -198.98%-4.19M | -85.63%851K |
-Change in receivables | 68.91%-1.04M | 78.02%-2.7M | -131.26%-1.47M | -163.80%-578K | 10.38%3.71M | 47.31%-3.34M | -100.13%-12.3M | 387.39%4.7M | 129.65%906K | -25.37%3.36M |
-Change in inventory | 53.85%-372K | 645.45%300K | 142.91%357K | -462.98%-1.02M | -103.82%-10K | 83.92%-806K | 91.60%-55K | 45.15%-832K | 87.79%-181K | 119.31%262K |
-Change in payables and accrued expense | 84.84%-1.28M | 38.37%-710K | 124.98%342K | 235.67%2.4M | 19.97%-3.32M | -168.22%-8.44M | -145.52%-1.15M | -170.21%-1.37M | -120.19%-1.77M | -364.87%-4.14M |
-Change in other working capital | --1.27M | --5.55M | 8.84%-2.52M | 23.22%-2.41M | -53.00%643K | ---- | ---- | -1,857.96%-2.76M | -44,757.14%-3.14M | -62.67%1.37M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 56.05%31.46M | 3,104.64%6.22M | -15.66%6.87M | 983.87%8.4M | -9.72%9.97M | -9.56%20.16M | 114.93%194K | 112.08%8.14M | -91.03%775K | -0.60%11.04M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -159.03%-28.59M | -217.62%-7.53M | -184.80%-9.95M | -323.74%-8.48M | 17.19%-2.63M | 79.51%-11.04M | 55.56%-2.37M | 73.23%-3.49M | 57.00%-2M | 89.71%-3.17M |
Net PPE purchase and sale | -184.20%-24.19M | -210.15%-7.12M | -213.89%-6.6M | -384.61%-8.16M | 4.65%-2.32M | 60.23%-8.51M | 59.42%-2.3M | 75.09%-2.1M | 66.52%-1.68M | -6.53%-2.43M |
Net intangibles purchase and sale | 31.56%-1.73M | -440.26%-416K | 64.22%-498K | -59.75%-508K | 58.54%-306K | 20.22%-2.53M | -129.96%-77K | -60.18%-1.39M | 77.76%-318K | 34.28%-738K |
Net business purchase and sale | ---2.67M | --0 | ---2.86M | --185K | --0 | --0 | --0 | --0 | --0 | --0 |
Net other investing changes | --1K | ---- | ---- | ---- | 200.00%1K | ---- | ---- | ---- | --0 | ---1K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -159.02%-28.59M | -217.58%-7.53M | -184.88%-9.95M | -323.79%-8.48M | 17.25%-2.62M | 79.51%-11.04M | 55.56%-2.37M | 73.23%-3.49M | 57.00%-2M | 89.71%-3.17M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -23.59%-27.65M | -211.50%-12.57M | 13.64%-6.09M | 29.84%-2.99M | 14.57%-6M | 0.63%-22.37M | 9.83%-4.04M | -3.68%-7.05M | -12.77%-4.27M | 5.84%-7.02M |
Net issuance payments of debt | -30.17%-26.39M | -282.20%-12.61M | 17.95%-5.43M | 29.53%-2.73M | 13.26%-5.63M | 3.86%-20.27M | 1.23%-3.3M | 6.36%-6.61M | -0.81%-3.87M | 5.20%-6.49M |
Net common stock issuance | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- | --0 |
Cash dividends paid | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Net other financing activities | 123.70%82K | 200.94%323K | -5,957.14%-410K | 133.33%175K | 94.44%-6K | -163.60%-346K | 61.63%-320K | -99.09%7K | -89.16%75K | -24.14%-108K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -23.59%-27.64M | -211.53%-12.57M | 13.63%-6.09M | 29.86%-2.99M | 14.56%-6M | 0.63%-22.37M | 9.85%-4.03M | -3.68%-7.05M | -12.74%-4.27M | 5.81%-7.02M |
Net cash flow | ||||||||||
Beginning cash position | -9.44%127.57M | -13.28%116.16M | -7.92%125.49M | -9.05%128.9M | -9.44%127.57M | -28.14%140.87M | -11.07%133.95M | -18.94%136.29M | -16.44%141.72M | -28.14%140.87M |
Current changes in cash | -87.02%-24.78M | -123.54%-13.88M | -282.40%-9.17M | 44.09%-3.07M | 57.85%1.35M | 75.50%-13.25M | 44.09%-6.21M | 85.02%-2.4M | -2,902.55%-5.49M | 103.14%854K |
Effect of exchange rate changes | -969.57%-492K | 114.79%25K | -340.91%-159K | -679.31%-336K | -2,100.00%-22K | 95.73%-46K | -112.47%-169K | 104.39%66K | 103.47%58K | -100.13%-1K |
End cash Position | -19.81%102.3M | -19.81%102.3M | -13.28%116.16M | -7.92%125.49M | -9.05%128.9M | -9.44%127.57M | -9.44%127.57M | -11.07%133.95M | -18.94%136.29M | -16.44%141.72M |
Free cash flow | -39.51%5.08M | 31.60%-1.54M | -110.87%-459K | 95.68%-58K | -8.17%7.14M | 437.91%8.4M | 65.74%-2.26M | 175.40%4.22M | -164.37%-1.34M | 2.13%7.77M |
Currency Unit | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |